Home > Specialties > IVD Test Reagent/Kits, Immunoassay, Autoimmune, Antineutrophil Cytoplasmic Antibody, Myeloperoxidase

IVD Test Reagent/Kits, Immunoassay, Autoimmune, Antineutrophil Cytoplasmic Antibody, Myeloperoxidase

Definition : Immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (e.g., serum) to determine myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA). Increased circulating levels of MPO-ANCA are associated with chronic lesions and slow deterioration of renal function; they are also found in autoimmune connective tissue diseases. Many patients identified with perinuclear-ANCA using indirect immunofluorescence, a less specific method, have antibodies to MPO-ANCA.

Entry Terms : "Myeloperoxidase Antineutrophil Cytoplasmic Antibody (MPO-ANCA) Determination Reagents" , "MPO-ANCA (Myeloperoxidase Antineutrophil Cytoplasmic Antibody) Determination Reagents" , "Reagents, Immunoassay, Autoimmune, Antineutrophil Cytoplasmic Antibody, Myeloperoxidase"

UMDC code : 20114

Filters
Manufacturers
Distributors
U.S.companies only
Suppress Subsidiary Companies
   

1-5 of 5 Match(es).

eBioscience Inc

Company Type: Parent

Established in San Diego, CA in 1999, eBioscience is a world leader in immunology and oncology flow cytometry reagents. As a privately held company, eBioscience offers one of the world's largest selections of antibodies, ELISAs and proteins for Life Science research and diagnostic.

Hemagen Diagnostics Inc

Company Type: Parent

Hemagen Inc. was founded in 1985 by a group of scientists from the Boston University School of Medicine.

Mayo Medical Laboratories

Company Type: Parent

ScienCell Research Laboratories

Company Type: Parent

Zeus Scientific Inc

Company Type: Parent

ZEUS Scientific is a privately held corporation that was founded in 1976. The company began producing IFA (immunofluorescence assay) test systems followed ELISA and now multiplex (AtheNA Multi-Lyte) immunoassays. New products are developed to expand the menu which allows laboratories to run an increasing number of assays with common protocols and common reagents, as well as developing new tests to more accurately diagnose patients. In 1987 ZEUS Scientific was the first company to develop, receive appropriate regulatory clearance and bring to market a serological assay to test for Lyme disease – a condition with high prevalence in the local community where ZEUS Scientific is located.

1-5 of 5 Match(es).